Somatostatin is a peptide hormone secreted by the pituitary gland, pancreas, and gastrointestinal endocrine cells that regulates the secretion of endocrine hormones via five G-protein-coupled receptors (Somatostatin receptor, SSTR1–5). We primarily focused on SSTR5 and identified SCO-240, an orally available selective SSTR5 antagonist. Despite extensive research, the in vivo physiological role of SSTR5 in humans remains unknown.
We conducted a Phase 1 trial in healthy individuals to evaluate the single-dose profile of SCO-240. Notably, SCO-240 stimulated a robust growth hormone (GH) secretion without affecting the secretion of other pituitary hormones. This is the first clinical report, which suggests that SSTR5 antagonist has a pivotal role in stimulating GH secretion in humans. Overall, SCO-240 is safe and well-tolerated and exhibits once-daily oral dosing potential. Collectively, SCO-240-mediated SSTR5 antagonism is a novel oral therapy for GH-related disorders, including pediatric GH deficiency (PGHD). In addition, research evidence suggests that SCO-240 may also be effective in treating female infertility and alopecia, and detailed information is available upon request.
SCOHIA is actively seeking partnerships worldwide for the development and commercialization of SCO-240 (Contact here for partnering).
Indication ：
- Growth hormone deficiency
- Infertility
- Alopecia
Scientific Publication
-
Presentation of clinical data of SCO-240 at the 96th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders
Link
Business
-
SCO-240, a Clinical Program for Pediatric Growth Hormone Deficiency, Was Selected as a Support Program of AMED
Link
Clinical Trial Information
-
SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)
Link